| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ludovic Samalin, Lila Mekaoui, Maud Rothärmel, Anne Sauvaget, Clotilde Wicart, Julien Dupin, Vanessa Cohignac, Emeline Gaudre-Wattinn. Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study. Depression and anxiety. vol 2024. 2025-04-14. PMID:40226655. |
use of esketamine nasal spray in patients with treatment-resistant depression in routine practice: a real-world french study. |
2025-04-14 |
2025-04-16 |
Not clear |
| Ludovic Samalin, Lila Mekaoui, Maud Rothärmel, Anne Sauvaget, Clotilde Wicart, Julien Dupin, Vanessa Cohignac, Emeline Gaudre-Wattinn. Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study. Depression and anxiety. vol 2024. 2025-04-14. PMID:40226655. |
the efficacy and safety of esketamine nasal spray (esk) were established in registration trials in patients with treatment-resistant depression (trd). |
2025-04-14 |
2025-04-16 |
Not clear |
| Patricio Molero, Angela Ibañez, Javier de Diego-Adeliño, J Antoni Ramos-Quiroga, Marta García Dorado, Paola M López Rengel, Pilar A Sai. A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study. Advances in therapy. 2025-03-19. PMID:40106175. |
a real-world study on the use, effectiveness, and safety of esketamine nasal spray in patients with treatment-resistant depression: integrate study. |
2025-03-19 |
2025-03-22 |
Not clear |
| Patricio Molero, Angela Ibañez, Javier de Diego-Adeliño, J Antoni Ramos-Quiroga, Marta García Dorado, Paola M López Rengel, Pilar A Sai. A Real-World Study on the Use, Effectiveness, and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: INTEGRATE Study. Advances in therapy. 2025-03-19. PMID:40106175. |
the integrate study aimed to provide information on the use, effectiveness, and safety of esketamine nasal spray (esk-ns) for the treatment of treatment-resistant depression (trd) in real-world practice in spain. |
2025-03-19 |
2025-03-22 |
Not clear |
| Lina Klysing, Ingrid Larsson, Katrin Häggström Westber. Person-centred care during treatment with nasal esketamine - a qualitative study. BMC nursing. vol 24. issue 1. 2025-03-15. PMID:40087713. |
patients suffering from treatment-resistant depression may be treated with nasal esketamine. |
2025-03-15 |
2025-03-18 |
Not clear |
| Sanjay J Mathew, Nicholas Murph. Six Years After Approval of Esketamine Nasal Spray for Serious Depression: Clinical Conundrums and Unanswered Questions. The American journal of psychiatry. vol 182. issue 3. 2025-03-01. PMID:40022533. |
six years after approval of esketamine nasal spray for serious depression: clinical conundrums and unanswered questions. |
2025-03-01 |
2025-03-04 |
Not clear |
| Yannan Ouyang, Juan L. Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. Medicine. vol 104. issue 9. 2025-02-28. PMID:40020133. |
efficacy of esketamine nasal spray for treatment-resistant depression: a meta-analysis of randomized controlled studies. |
2025-02-28 |
2025-03-03 |
Not clear |
| Yannan Ouyang, Juan L. Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. Medicine. vol 104. issue 9. 2025-02-28. PMID:40020133. |
the efficacy of esketamine nasal spray for treatment-resistant depression remains controversial. |
2025-02-28 |
2025-03-03 |
Not clear |
| Yannan Ouyang, Juan L. Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. Medicine. vol 104. issue 9. 2025-02-28. PMID:40020133. |
this systematic review and meta-analysis was conducted to explore the influence of esketamine nasal spray on treatment efficacy for treatment-resistant depression. |
2025-02-28 |
2025-03-03 |
Not clear |
| Matildes de Freitas Menezes Sobreiro, Paulo Sergio Panse Silveira, Vitor Breseghello Cavenaghi, Leandro Paulino da Costa, Bruno Pinatti Ferreira de Souza, Rachel Emy Straus Takahashi, Renato Vianna Marotta Starek, José Oliveira Siqueira, Renerio Fragua. Long-Term Cognitive Outcomes of Esketamine Nasal Spray in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals (Basel, Switzerland). vol 18. issue 2. 2025-02-26. PMID:40005986. |
long-term cognitive outcomes of esketamine nasal spray in treatment-resistant depression: a preliminary report. |
2025-02-26 |
2025-02-28 |
Not clear |
| Eduard Vieta, Nahida Ahmed, Celso Arango, Anthony J Cleare, Koen Demyttenaere, Markus Dold, Tetsuro Ito, Yerkebulan Kambarov, Stephanie Krüger, Pierre-Michel Llorca, Roger S McIntyre, Gabriele Sani, Christian von Holt, Benoit Riv. Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 93. 2025-02-09. PMID:39923271. |
improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: findings from a 32-week randomised, open-label, rater-blinded phase iiib study. |
2025-02-09 |
2025-02-13 |
Not clear |
| Zhiqi Shi, Qing Wang, Qing Li, Fan Jia, Weifeng X. Oleanolic Acid Cubic Liquid Crystal Nanoparticle-Based Thermosensitive Gel Attenuates Depression Symptoms in Chronic Unpredictable Mild Stress Rats. Drug design, development and therapy. vol 19. 2025-02-06. PMID:39911446. |
in this study, building upon a previous formulation of oa cubic liquid crystal nanoparticles (oa-lcnp), we combined nanoparticles with a thermosensitive gel for nasal administration and investigated the pharmacological effects of oa-lcnp thermosensitive gel (oang) on depression. |
2025-02-06 |
2025-02-08 |
rat |
| Kristin Clemens, Amanda Teeple, Maryia Zhdanava, Aditi Shah, Kruti Joshi, Jozefien Buyze, Dominic Pilon, Hannah E Bowrey, Yordan Godino. Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression. The Journal of clinical psychiatry. vol 86. issue 1. 2025-02-03. PMID:39898892. |
esketamine nasal spray vs quetiapine extended-release: examining work productivity loss and related costs in patients with treatment-resistant depression. |
2025-02-03 |
2025-02-05 |
Not clear |
| Manish K Jha, Maryia Zhdanava, Aditi Shah, Arthur Voegel, Anabelle Tardif-Samson, Dominic Pilon, Kruti Josh. Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA. Drugs - real world outcomes. 2025-01-19. PMID:39828878. |
mental health-related disability days and costs among patients with treatment-resistant depression initiated on esketamine nasal spray and conventional therapies in the usa. |
2025-01-19 |
2025-01-23 |
Not clear |
| Roger S McIntyre, Gregory Mattingly, Yordan Godinov, Jozefine Buyze, Ibrahim Turkoz, Patricia Cabrera, Manish Patel, Larry Martinez, Mai Himedan, Oliver Lopen. Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial. CNS spectrums. 2025-01-17. PMID:39819527. |
esketamine nasal spray versus quetiapine xr in adults with treatment-resistant depression: a secondary analysis of the escape-trd randomized clinical trial. |
2025-01-17 |
2025-01-20 |
Not clear |
| Gianluca Rosso, Giacomo d'Andrea, Stefano Barlati, Marco Di Nicola, Ileana Andriola, Matteo Marcatili, Vassilis Martiadis, Miriam Olivola, Stefania Di Mauro, Gabriele Di Salvo, Pasquale De Fazio, Massimo Clerici, Bernardo Maria Dell'Osso, Antonio Vita, Giorgio Di Lorenzo, Mauro Pettorruso, Giovanni Martinotti, Giuseppe Main. Esketamine Treatment Trajectory of Patients with Treatment-Resistant Depression in the Mid and Long-Term Run: Data from REAL-ESK Study Group. Current neuropharmacology. vol 23. issue 5. 2025-01-15. PMID:39810448. |
data on long-term treatment with esketamine nasal spray (eskns) in real-world patients with treatment resistant depression (trd) is scarce. |
2025-01-15 |
2025-01-17 |
Not clear |
| Zhibin Wang, Lili Jiang, Wenzhuang Ma, Xingyue Li, Qiushi Gao, Siyu Lian, Weiwei Y. Esketamine Nasal Spray in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Clinical pharmacology and therapeutics. 2025-01-10. PMID:39790081. |
comprehensive retrieval in embase, pubmed, and web of science was conducted to identify randomized controlled trials comparing esketamine nasal spray versus control in major depressive disorder or treatment-resistant depression. |
2025-01-10 |
2025-01-13 |
Not clear |
| Zhibin Wang, Lili Jiang, Wenzhuang Ma, Xingyue Li, Qiushi Gao, Siyu Lian, Weiwei Y. Esketamine Nasal Spray in Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. Clinical pharmacology and therapeutics. 2025-01-10. PMID:39790081. |
esketamine nasal spray was superior to placebo in reduction of montgomery-asberg depression rating scale from baseline to day 28 in patients without suicidal ideation (standardized mean difference: -0.24, 95% confidence interval: -0.38, -0.09, p = 0.001, i |
2025-01-10 |
2025-01-13 |
Not clear |
| Kristin Clemens, Maryia Zhdanava, Amanda Teeple, Arthur Voegel, Kruti Joshi, Aditi Shah, Cindy Chen, Dominic Pilo. Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States. Journal of managed care & specialty pharmacy. 2024-12-20. PMID:39704732. |
impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the united states. |
2024-12-20 |
2024-12-22 |
Not clear |
| Kristin Clemens, Maryia Zhdanava, Amanda Teeple, Arthur Voegel, Kruti Joshi, Aditi Shah, Cindy Chen, Dominic Pilo. Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States. Journal of managed care & specialty pharmacy. 2024-12-20. PMID:39704732. |
however, there is limited knowledge regarding these socioeconomic factors with respect to initiation of esketamine nasal spray, a novel therapy for treatment-resistant depression (trd). |
2024-12-20 |
2024-12-22 |
Not clear |